Positive data to be presented at conference for dupilumab in open label extension study in asthma

Analysis including data from >2200 patients who previously participated in trials, including 3 pivotal trials lasting between 24 and 52 weeks noted improved lung function by 13-22% at 3 years vs baseline, and maintenance of lower rate of severe asthma attacks


Biospace Inc.